Skip to main content

Xifaxan News

ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin

MONDAY, Oct. 28, 2024 – For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according...

FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)

LAVAL, Quebec, May 27, 2015 /PRNewswire/ – Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received...

FDA Approves New Use of Xifaxan for Patients with Liver Disease

SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Irritable Bowel Syndrome, Diarrhea

Xifaxan patient information at Drugs.com